Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03681808 · ClinicalTrials.gov registry record · NA
Evaluate the Safety and Effectiveness of the Biotrue ONEday for Astigmatism
A NA study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- NA
- Development phase
- 242
- Enrollment target
NCT03681808: Completed NA study, sponsored by Bausch & Lomb Incorporated.
NCT03681808 is a NA study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 242 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03681808, a NA study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- NA
- Development phase
- 242 participants
- Enrollment target
Study Summary
Comparing Test Lens for Astigmatism Soft Contact Lens (Test) to 1-Day Control for Astigmatism contact lenses (Control).
Primary Outcome
The proportion of participants achieving a contact lens corrected distance logMAR VA of 0.04 or better in both eyes
Interventions
- DEVICE Control
- DEVICE Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2018-10-10 |
| Est. Completion | 2019-12-16 |
| Phase | NA |
What the finished NCT03681808 record still lists
NCT03681808 is an interventional study that assigns participants to a tested intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT03681808 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03681808 about?
NCT03681808 is a clinical study titled "Evaluate the Safety and Effectiveness of the Biotrue ONEday for Astigmatism". Comparing Test Lens for Astigmatism Soft Contact Lens (Test) to 1-Day Control for Astigmatism contact lenses (Control).
What is the current status of trial NCT03681808?
This trial is currently completed. It is a NA study. The enrollment target is 242 participants. The study started on 2018-10-10. Estimated completion is 2019-12-16.
What interventions are being tested in trial NCT03681808?
The interventions under investigation include: Control (DEVICE), Test (DEVICE).
Who is sponsoring clinical trial NCT03681808?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03681808's enrollment target sits among peer trials
242 439th of 2000 higher than 1,561 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI